Across rheumatic diseases

The predictive accuracy of cardiovascular disease risk prediction tools in inflammatory arthritis and psoriasis: an observational validation study using the Clinical Practice Research Datalink

Rheumatology (Oxford)Published Observational validation study

Authors' conclusion

CVD risk for individuals with RA, AS and psoriatic disease was generally less accurately predicted using each of the three CVD risk prediction tools than the reported accuracies in the original publications. Individuals with OA also had less accurate predictions, suggesting inflammation is not the sole reason for underperformance.

Study context

Population
Individuals with RA, psoriatic disease (PsA and psoriasis), AS or OA in Clinical Practice Research Datalink (CPRD) Aurum primary care records
Comparison
QRISK3 vs Framingham Risk Score (FRS) vs Reynolds Risk Score (RRS) for 10-year CVD risk prediction across RA, AS, PsA, psoriasis and OA
Outcome
Discrimination and calibration of QRISK3, FRS and RRS for 10-year CVD risk
Follow-up
10 years
Methodological detailsCPRD Aurum primary care records, time-dependent AUC
  • CPRD Aurum primary care records
  • Time-dependent AUC

Performance

As reported in the abstract

Time-dependent AUC for QRISK3
Test or modelAUC
RA0.752 (95% CI 0.734-0.777)
AS0.794 (95% CI 0.764-0.812)
PsA0.764 (95% CI 0.741-0.791)
Psoriasis0.815 (95% CI 0.789-0.835)
OA0.698 (95% CI 0.670-0.717)

AUC

RA0.752 (95% CI 0.734-0.777)
AS0.794 (95% CI 0.764-0.812)
PsA0.764 (95% CI 0.741-0.791)
Psoriasis0.815 (95% CI 0.789-0.835)
OA0.698 (95% CI 0.670-0.717)

Further findings

Calibration

FRS reasonably well calibrated for each condition but underpredicted risk in RA
RRS tended to underpredict CVD risk
QRISK3 overpredicted CVD risk, especially for the most high-risk individuals

Original publication

The predictive accuracy of cardiovascular disease risk prediction tools in inflammatory arthritis and psoriasis: an observational validation study using the Clinical Practice Research Datalink. Rheumatology (Oxford). Published 15 November 2023. doi:10.1093/rheumatology/kead610

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.